Anixa Biosciences (ANIX) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Anixa Biosciences (ANIX) has outperformed Organigram Global (OGI) over the past year, losing 43.8% versus a loss of 60.6%. Over five years, ANIX leads with a -38.7% price change compared with -93.3% for OGI. Anixa Biosciences is the larger company by market cap ($84.8 million vs $82.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | OGI |
|---|---|---|
| Share price | $2.44 | $0.583 |
| Market cap | $84.82M | $82.27M |
| 1-day change | -6.15% | -7.40% |
| YTD return | -21.79% | -65.30% |
| 1-year return | -43.78% | -60.61% |
| 5-year return | -38.69% | -93.25% |
| P/E ratio (TTM) | — | 1.36 |
| Forward P/E | — | 27.76 |
| EPS (TTM) | $-0.32 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-10.93M | — |
| 52-week high | $5.46 | $2.24 |
| 52-week low | $2.32 | $0.583 |
| Distance from 52-week high | -55.31% | -73.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +296.31% | — |
| Average volume | 282.29K | 567.77K |
| Shares outstanding | 34.76M | 141.11M |
| Employees | 4 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIX has outperformed OGI by 16.8 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
ANIX vs OGI FAQ
Which is bigger, Anixa Biosciences or Organigram Global?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $84.82M compared with $82.27M for Organigram Global (OGI).
Which stock has performed better over the past year, ANIX or OGI?
ANIX returned -43.78% over the past 12 months, compared with -60.61% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Organigram Global in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.